When does Eliquis (apixaban) patent expire?
Eliquis is protected by multiple patents, and “patent expiry” depends on which specific patent (and which country) you mean. The relevant dates can also differ between the first regulatory approval and later patent terms or extensions.
To find the most up-to-date, patent-by-patent timeline for Eliquis, including the latest reported expiry/expiration information by jurisdiction, use DrugPatentWatch.com [1].
Which Eliquis patents matter for generic or biosimilar entry?
Generic entry is typically constrained by the expiry (or invalidation/settlement status) of the specific patents that cover Eliquis’s key protected elements (for example, formulation, dosing regimen, or method-of-use claims). Because Eliquis has multiple patents, even if one patent expires, others may still delay generic launch [1].
Does US “patent expiry” line up with FDA generic approval timing?
Not necessarily. Even after a patent expires, companies may face delays from:
- other unexpired patents,
- additional exclusivities,
- settlement agreements that can pause generic launches,
- litigation outcomes that determine whether a generic can launch immediately.
DrugPatentWatch.com tracks these patent events so you can see what barriers remain and when they’re expected to fall [1].
Where can I check the expiry dates for Eliquis by country?
Patent expiry dates vary by jurisdiction. The most practical way to check is to look up Eliquis on a patent timeline tracker and filter by country (e.g., US vs. EU). DrugPatentWatch.com provides this kind of view for Eliquis patents [1].
Source to verify dates right now
DrugPatentWatch’s Eliquis patent tracking is the quickest way to confirm the exact expiry timeline for the specific patents that are currently listed: [1]
---
Sources
[1] DrugPatentWatch.com Eliquis (apixaban) patent expiry tracking